Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981187 · ClinicalTrials.gov registry record · Phase 2
LGX818 for Patients With BRAFV600 Mutated Tumors
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01981187 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT01981187, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
Interventions
- DRUG LGX818
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-01-14 |
| Est. Completion | 2015-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981187
The ClinicalTrials.gov registry entry for NCT01981187 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LGX818 is the first listed.
NCT01981187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981187 about?
NCT01981187 is a clinical study titled "LGX818 for Patients With BRAFV600 Mutated Tumors". The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
What is the current status of trial NCT01981187?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2014-01-14. Estimated completion is 2015-10-13.
What interventions are being tested in trial NCT01981187?
The interventions under investigation include: LGX818 (DRUG).
Who is sponsoring clinical trial NCT01981187?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.